VR Logo

Pasithea Therapeutics Corp. (KTTA) download report


Healthcare | Biotechnology & Pharma Research

Pasithea Therapeutics Corp. (KTTA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders.

IPO Date: 15-Sep-2021

Exec. Chairman & Co-Founder: Prof. Lawrence Steinman BA, M.D.

CEO & Director: Dr. Tiago Reis Marques

Listing: NASDAQ: KTTA

Country: United States

Headquarters: Miami Beach, FL

Website: https://www.pasithea.com

Key Facts

Market cap: $22.56 Mln

Revenue (TTM): $0.03 Mln

Earnings (TTM): $-3.20 Mln

Cash: $50.32 Mln

Total Debt: $0.00 Mln

Insider's Holding: 10.48%

Liquidity: Low

52 Week range: $0.81 - 8.50

Shares outstanding: 23,287,800

Stock Performance

Time Period Pasithea Therapeutics (KTTA) S&P BSE Sensex S&P Small-Cap 600
YTD-43.50-8.74-17.05
1 month21.07-2.01-4.75
3 months-25.37-7.32-12.65
1 Year--0.45-16.28
3 Years--10.328.01
5 Years--11.296.35
10 Years--12.1410.55
As on 27-Jun-2022